Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jan 12, 2024
Smart Investing: $TLRY Rakes in +5.02% Profits via Automated Trading.

Smart Investing: $TLRY Rakes in +5.02% Profits via Automated Trading.

Artificial intelligence-powered trading robots have been making waves, demonstrating their capabilities in the volatile world of finance. At "Trend Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)," these AI-driven bots successfully generated a remarkable +5.02% gain while trading TLRY over the previous week. In this article, we delve into the technical analysis of TLRY's recent performance, focusing on key indicators, earnings results, market capitalization, and notable price and volume movements within the Pharmaceuticals: Other Industry.

Technical Indicator Insights: TLRY's RSI Oscillator

One notable technical signal for TLRY is the movement of its 10-day Relative Strength Index (RSI) Oscillator. On December 29, 2023, the RSI moved out of the overbought zone, suggesting a potential shift from an upward to a downward trend. According to Tickeron's A.I.dvisor, in 15 out of 16 instances where the RSI exited the overbought zone, the stock moved lower in the subsequent days. This statistical pattern places the odds of a downward move at a substantial 90%. Traders are advised to consider selling the stock or exploring put options in response to this signal.

Earnings Report Overview: January 09, 2024

TLRY's latest earnings report, dated January 09, 2024, revealed earnings per share of -7 cents, falling short of the estimated -5 cents. The company, with 12.73 million shares outstanding, currently holds a market capitalization of 1.29 billion. Analyzing the earnings miss and its impact on the stock's valuation provides valuable insights for investors considering their positions in TLRY.

Market Capitalization Comparison in Pharmaceuticals: Other Industry

Comparing TLRY's market capitalization with industry peers is crucial for understanding its relative standing. In the Pharmaceuticals: Other Industry, the average market capitalization is 2.79 billion, with a range spanning from 246 million (PEMTF) to a staggering 82.08 billion (ZTS). TLRY's position within this spectrum influences its attractiveness to investors and potential for future growth.

Price Movement Metrics: Highs, Lows, and Industry Averages

Analyzing TLRY's price movements alongside industry benchmarks provides context for evaluating its performance. The average weekly, monthly, and quarterly price growth across all stocks in the Pharmaceuticals: Other Industry stands at 0%, 34%, and 21%, respectively. TLRY's individual price trajectory becomes more apparent when compared to its industry counterparts, offering insights into its relative strength and weaknesses.

Notable high and low price movements within the industry further highlight TLRY's performance. With UPC experiencing the highest price growth at 66%, and CNGGF witnessing a significant fall at -52%, understanding these extremes aids in contextualizing TLRY's own price dynamics.

Volume Trends in Pharmaceuticals: Other Industry

Examining TLRY's trading volume alongside industry trends is essential for assessing investor sentiment. The average weekly, monthly, and quarterly volume growth across all stocks in the Pharmaceuticals: Other Industry is -3%, 34%, and -17%, respectively. TLRY's volume trends, compared to industry averages, provide valuable insights into the level of interest and activity surrounding the stock.

In summary, the technical analysis of TLRY's recent performance, encompassing indicators, earnings results, market capitalization, price movements, and volume trends, offers investors a comprehensive understanding of the stock's current position and potential future trajectory.

Related Ticker: TLRY

Momentum Indicator for TLRY turns negative, indicating new downward trend

TLRY saw its Momentum Indicator move below the 0 level on June 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In of the 79 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for TLRY entered a downward trend on July 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Oscillator exited the oversold zone, of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where TLRY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TLRY just turned positive on July 02, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .

TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.356) is normal, around the industry mean (79.618). P/E Ratio (0.000) is within average values for comparable stocks, (97.708). TLRY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.629). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.571) is also within normal values, averaging (95.237).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.11B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 2%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 13%. UPC experienced the highest price growth at 123%, while AKAN experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -37%. For the same stocks of the Industry, the average monthly volume growth was -28% and the average quarterly volume growth was -50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 66
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 82
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
TLRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
1600
Web
https://www.tilray.com
Interact to see
Advertisement
TSM shares have remained relatively resilient despite heightened volatility, supported by the ongoing global buildout of AI infrastructure. Investor attention has centered on capacity expansion updates and signals from major customers, particularly in high-performance computing. While execution risks remain in the near term, leadership in advanced manufacturing and packaging continues to anchor TSM’s long-term growth narrative, even as global supply chains face scrutiny.
Rivian (RIVN) is carving out a distinct position in the electric vehicle market by targeting adventure-focused consumers, commercial fleets, and long-term sustainable transportation solutions. As the EV industry moves beyond early adoption toward scalability and efficiency, Rivian is emphasizing broader product offerings, streamlined manufacturing, and software-enabled services.
Aon plc (AON) reported third-quarter 2025 revenue of $3.997 billion, representing a 7% year-over-year increase with equal organic growth. Adjusted earnings per share came in at $3.05, exceeding expectations. In late November, Moody’s reaffirmed Aon’s Baa2 credit rating and revised the outlook to positive, citing reduced leverage following the NFP acquisition.
General Motors (GM) is in the midst of a long-term transformation, evolving from a traditional automotive manufacturer into a technology-focused mobility company. By combining its global scale, manufacturing capabilities, and well-known brands, GM is accelerating its push into electric vehicles, software-defined platforms, and autonomous systems, while continuing to generate cash from its internal-combustion portfolio.
Air Products and Chemicals, Inc. (APD) entered the spotlight after announcing advanced discussions with Yara International on December 8 to collaborate on low-emission ammonia projects. While the strategic direction aligns with global decarbonization trends, uncertainty around execution and capital requirements triggered a 9.45% one-day decline in the stock.
APO shares have traded in a relatively tight range recently, consolidating near the $148 level. The stock reflects investor confidence in Apollo’s expanding asset base, record fee earnings, and disciplined execution amid renewed interest in alternative assets. Growth in retirement services through Athene continues to provide stability, helping offset volatility across private equity and credit markets.
Lockheed Martin and RTX Corporation are two of the most prominent names in the aerospace and defense industry, both positioned to benefit from heightened global security concerns and sustained U.S. military spending.
Eli Lilly and Novo Nordisk are among the most influential pharmaceutical companies in the rapidly expanding GLP-1 receptor agonist market, which targets diabetes and obesity. As competition intensifies and regulatory and pricing dynamics evolve, the divergence in their stock performance has become increasingly pronounced.
Lumentum and Ciena are leading players in the optical networking sector, positioned to capitalize on surging demand for high-speed data transmission driven by AI, cloud computing, and 5G rollouts. Their business models, however, diverge significantly: LITE focuses on specialized photonic components, while CIEN offers broader networking solutions.
As 2025 winds down, the Savings Banks sector reflects a mix of stability, innovation, and AI-driven disruption. Among the most closely watched tickers—SOFI Technologies (SOFI), Ally Financial (ALLY), and PayPal Holdings (PYPL)—investors have witnessed contrasting stories of growth, valuation, and market perception.
As 2025 comes to a close, financial markets remain dynamic, with technology and entertainment stocks capturing investor attention. Streaming platforms, in particular, are navigating content consolidation, evolving consumer preferences, and digital monetization shifts. Netflix (NFLX), Disney (DIS), and Spotify (SPOT) stand out as major players at the intersection of streaming, entertainment, and technology.
Ondas Holdings (ONDS) is a wireless technology company focused on delivering secure, long-range communications for industrial Internet of Things (IoT) and data networking applications. Its solutions are built to support mission-critical operations across sectors such as rail, energy, maritime, infrastructure, and industrial automation.
Ciena’s growth is driven by expanding offerings in optical networking, network automation software, and 5G transport infrastructure, complemented by services designed to help customers modernize and future-proof their networks. Its evolving technology portfolio addresses the rising complexity, speed, and reliability requirements of today’s communications environment.
Marathon Digital Holdings (MARA) and Riot Platforms (RIOT) are two leading companies in the Bitcoin mining industry, each operating energy-intensive infrastructure to capitalize on cryptocurrency market cycles. This comparison is especially relevant amid ongoing Bitcoin price volatility and growing interest in digital assets and AI-related infrastructure.
Roivant Sciences has delivered strong year-to-date performance, with shares up roughly 82%, driven by encouraging pipeline developments and increased investment in high-potential subsidiaries such as Immunovant.
MP Materials Corp. (MP) and USA Rare Earth, Inc. (USAR) are central to the United States’ push to establish a secure, domestic supply of rare earth elements—materials critical to electric vehicles, renewable energy, and defense technologies. As geopolitical tensions and supply chain vulnerabilities intensify, these two companies offer distinct approaches to addressing U.S. dependence on foreign sources.
SanDisk (SNDK) Corporation has emerged as one of the strongest performers in the semiconductor storage space, benefiting from its central role in AI infrastructure buildouts. The stock has risen more than fivefold from recent cycle lows, fueled by accelerating demand for high-capacity NAND flash and solid-state drives essential for data-intensive workloads.
As markets move into 2026, the outlook for SPY remains cautiously optimistic. Technical momentum, investor sentiment, and AI-driven forecasts align in favor of continued upside, assuming macroeconomic conditions remain stable and Federal Reserve policy evolves as expected.
Over the past year, the Direxion Daily Semiconductor Bull 3X Shares ETF (SOXL) has stood out as one of the market’s most volatile—and potentially rewarding—leveraged ETFs. Designed to deliver three times the daily performance of the ICE Semiconductor Index, SOXL closely tracks the heartbeat of the semiconductor industry, a sector at the core of global digital and AI transformation.
Smart Investing: $TLRY Rakes in +5.02% Profits via Automated Trading.